Wolfe Research analyst Alex Zukin maintains Salesforce.com (NYSE:CRM) with a Outperform and raises the price target from $290 to $300.
Where Ascendis Pharma Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
